IDIBELL Licenses to Janus a Patent for the Treatment of Immune Diseases
News Dec 06, 2012
The Bellvitge Biomedical Research Institute (IDIBELL) has signed a licensing agreement with the company Janus Developments of a patent for an immunomodulatory product for treating immune diseases such as autoimmune diseases, sepsis, hypersensitivity disorders (including, allergic reactions) or post-transplant rejection. The patent has been developed by the researcher of the Human Molecular Genetics group Josep Maria Aran and his team.
The invention relates to a concrete form of C4BP protein (C4b-binding protein), which is able to inhibit other proteins in the complement system, a major component of the innate immune response.
Step into the market
Many years will be needed before the product developed by Dr. Aran can be applied in humans. It will require additional preclinical studies and clinical trials in humans. In this sense, the signing of the license agreement is an important step to complete these studies and to become in the future a pharmaceutical product.
The head of the Technology Transfer Office (TTO) at IDIBELL, Montse Ballarín, highlights the fact that "the license products developed at our institution reflects the IDIBELL strategy as a public research centre, to bring our ideas and inventions to market."
Ballarín stresses that the transfer of a technology or a product to industry is not an easy process. "You have to offer a good product that meets a market need, to solve an unsolved problem, a technically and economically feasible production, a will to buy by the health system and a long list of conditions that are overcome before to achieve the interest of the company." Finally, "there is a good bargain to adequately protect the interests of inventors and the institution", explains the OTRI responsible.
Janus Developments is a company dedicated to biomedical knowledge transfer to the market. Currently develop eleven projects based on patents originated at several universities and research centres. In addition, Janus timely collaborates in defining and implementing various companies and foundations. Janus Developments supports IDIBELL in transfer activities, from identifying technologies to the introduction to market.
The license signed with Janus is the first patent that IDIBELL, through its TTO, has been transferred to a company outside the campus (previously had managed licensing contracts with spin-offs arising from the institution). Also recently it has been transferred a diagnostic technology and a patent to a multinational pharmaceutical company. At this time, IDIBELL is on track to close two licensing agreements over two patents developed by researchers at the centre.
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018